Form 4: Kura Oncology Insider Buys Shares Under 10b5-1 Plan

Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, acquired 2,256 shares of common stock through an Employee Stock Purchase Plan executed under a Rule 10b5-1 trading plan.

Summary

• Teresa Brophy Bair, Chief Legal Officer at Kura Oncology, Inc., acquired 2,256 shares of common stock on May 18, 2026.
• The acquisition was made through the company's Employee Stock Purchase Plan.
• This transaction was executed under a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
• The weighted average price for the shares acquired was $9.3795, with individual trades ranging from $9.28 to $9.49.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as insider purchases, even under a pre-arranged plan, can indicate confidence in the company's stock.

Positives

• Insider acquisition of company stock can signal confidence in the company's future prospects.
• The purchase was made under a pre-arranged Rule 10b5-1 plan, indicating a structured and non-opportunistic transaction.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage their personal portfolios while adhering to regulatory requirements. Such transactions can provide insights into management's perception of the company's valuation.

Stakeholder Impact

• Shareholders may view this insider purchase positively, interpreting it as a sign of management's confidence in the company's future performance.
• Employees participating in the Employee Stock Purchase Plan benefit from the structured acquisition of company stock.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Trading, Employee Stock Purchase Plan, Rule 10b5-1, Teresa Brophy Bair, Common Stock